Evidence map›Paper›PMID 34771454›Full record

ArticleCancers2021

REV1 Inhibition Enhances Radioresistance and Autophagy.

Kanayo E Ikeh, Erica N Lamkin, Andrew Crompton, Jamie Deutsch, Kira J Fisher, Mark Gray, David J Argyle, Won Y Lim, Dmitry M Korzhnev, M Kyle Hadden and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Sensitization of cancer cells to DNA-damaging agents by expression of the REV1 C-terminal domain: Implications for chemotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Kanayo E IkehDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA.
Erica N LamkinDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA.ORCID 0000-0002-2404-5129
Andrew CromptonDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA.ORCID 0000-0003-4835-5348
Jamie DeutschDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA.
Kira J FisherDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA.ORCID 0000-0002-5901-2503
Mark GrayThe Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush, Roslin, Midlothian, Edinburgh EH25 9RG, UK.ORCID 0000-0003-2035-1425
David J ArgyleThe Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush, Roslin, Midlothian, Edinburgh EH25 9RG, UK.
Won Y LimDepartment of Chemistry, Duke University, Durham, NC 27708, USA.
Dmitry M KorzhnevDepartment of Molecular Biology and Biophysics, University of Connecticut Health Center, Farmington, CT 06030, USA.
M Kyle HaddenDepartment of Pharmaceutical Sciences, University of Connecticut, 69 N Eagleville Rd, Unit 3092, Storrs, CT 06269-3092, USA.ORCID 0000-0001-9482-1712
Jiyong HongDepartment of Chemistry, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-5253-0949
Pei ZhouDepartment of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-7823-3416
Nimrat ChatterjeeDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA.
University of Vermont · USDuke University · USRoslin Institute · GBUConn Health · USUniversity of Connecticut · US

Funding

Inhibition of Translesion Synthesis as a Novel Strategy for Cancer ChemotherapyR01CA233959 · NCI · UNIVERSITY OF CONNECTICUT STORRS · PI HADDEN, MATTHEW KYLE, KORZHNEV, DMITRY M. · 2019 to 2023
$2.5M
NCI NIH HHS R01 CA233959University of Vermont Medical Center University of Vermont Cancer Center
6 · The paper itself

Abstract

Cancer therapy resistance is a persistent clinical challenge. Recently, inhibition of the mutagenic translesion synthesis (TLS) protein REV1 was shown to enhance tumor cell response to chemotherapy by triggering senescence hallmarks. These observations suggest REV1's important role in determining cancer cell response to chemotherapy. Whether REV1 inhibition would similarly sensitize cancer cells to radiation treatment is unknown. This study reports a lack of radiosensitization in response to REV1 inhibition by small molecule inhibitors in ionizing radiation-exposed cancer cells. Instead, REV1 inhibition unexpectedly triggers autophagy, which is a known biomarker of radioresistance. We report a possible role of the REV1 TLS protein in determining cancer treatment outcomes depending upon the type of DNA damage inflicted. Furthermore, we discover that REV1 inhibition directly triggers autophagy, an uncharacterized REV1 phenotype, with a significant bearing on cancer treatment regimens.

Indexed as

autophagyetoposideionizing radiationsradioresistanceREV1translesion synthesis

Identifiers

PMID34771454
PMCPMC8582445
OpenAlexW3206998322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.